Send us a text

Are stem-cell treatments the future of self-therapy and regenerative medicine?

Or is there something better?

In the latest episode of HealthBiz Briefs, host, David Williams, is joined by Pete O’Heeron, CEO of Fibrobiologics, explores the untapped potential of fibroblasts and their promise as a potentially superior and more affordable alternative to traditional stem-cell treatments.

🎙️⚕️ABOUT CARETALK
CareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (President U.S. Healthcare and EVP, Walgreens Boots Alliance) and David Williams (President, Health Business Group) as they debate the latest in US healthcare news, business and policy.

🎙️⚕️ABOUT PETE O'HEERON
Pete O'Heeron, an esteemed biopharma inventor, boasts over 300 patents in biologics, cell therapy, and medical devices. With 25+ years of expertise, he leads FibroBiologics as CEO, driving its emergence as a global leader in fibroblast-based cell therapies for chronic diseases. Previously, he founded Advanced Medical Technologies, identifying early-stage medical opportunities, and NeoSurg Technologies, known for the T2000 Minimally Invasive Access System sold to Cooper Surgical in 2006. With executive roles at Christus Health Care Corporation, strategic advisory, and academic background, including degrees from Texas State University, University of Houston Clear Lake, and University of Chicago,

GET IN TOUCH
Become a CareTalk sponsor
Guest appearance requests
Visit us on the web
Subscribe to the CareTalk Newsletter
Shop official CareTalk merch

FOLLOW CARETALK
Spotify
Apple Podcasts
Google Podcasts
Follow us on LinkedIn

#healthcarepodcast #healthcare #fibroblasts #fibroblastresearch #stemcells #stemcelltreatments #medicalbreakthroughs

Support the show

⚙️CareTalk: Healthcare. Unfiltered. is produced by Grippi Media Digital Marketing Consulting.